CTOs on the Move

Roivant

www.roivant.com

 
Roivant Sciences is a global healthcare company focused on realizing the full value of promising biomedical research to improve the lives of patients and their families. Roivant`s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the broader healthcare system. Roivant is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas. We deliver R&D solutions to our partners in the biopharmaceutical industry, helping them unlock value from their pipelines by completing the clinical development of promising drug candidates. Our pipeline spans multiple ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.roivant.com
  • 320 West 37th Street 5th Floor
    New York, NY USA 10018
  • Phone: 212.202.4650

Executives

Name Title Contact Details
Robert DuPuy
Head of Information Security Profile
Celine Chan
Chief Information Security Officer Profile

Similar Companies

QurAlis

QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms.

Chrysalis Scientific Technologies

Chrysalis Scientific Technologies Inc. is a Brampton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AIkido Pharma

AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.

GTC Biotherapeutics

GTC Biotherapeutics is a Framingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stelexis Therapeutics

Stelexis` mission is to become the leading cancer therapeutics company, through the discovery and development of novel drugs, utilizing its proprietary platform to selectively target pre-cancerous stem cells. The company will initially focus on therapeutics for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).